← Back to Events
GENERAL 7 DAYS AWAY
2026 U.S.-Japan Healthcare
<p>*In-person program Come hear pitches from leading Japanese strategic investors and pharmaceutical companies including AN Ventures, Astellas, Chugai Pharmaceuticals, Daiichi Sankyo, Nippon Life, and Ono Pharmaceuticals. Our presenters will share…</p>\n
75+ Attendees
Coverage & Analysis
🇺🇸 Latest Americas News
All news → May 5 Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas May 5 Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment May 5 CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis May 5 Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD May 5 Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD